Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Bone Biologics (Nasdaq: BBLG), a developer of orthobiologic products for spine fusion markets, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City. Jeffrey Frelick, the company's CEO, will deliver a virtual presentation, which will be accessible online starting September 9th at 7:00 a.m. Eastern time.
The presentation will remain available on the company's website for a time. Bone Biologics' management team will also be available for virtual one-on-one meetings throughout the conference. Institutional investors and industry professionals can choose to attend the conference either virtually or in-person at the Lotte New York Palace Hotel.
Bone Biologics (Nasdaq: BBLG), sviluppatore di prodotti ortobiologici per il mercato della fusione spinale, ha annunciato la sua partecipazione al 26° Annual Global Investment Conference di H.C. Wainwright. L'evento è programmato per il 9-11 settembre 2024, a New York City. Jeffrey Frelick, CEO dell'azienda, effettuerà una presentazione virtuale, che sarà accessibile online a partire dal 9 settembre alle 7:00 a.m. ora orientale.
La presentazione rimarrà disponibile sul sito web dell'azienda per un certo periodo. Il team di gestione di Bone Biologics sarà anche disponibile per incontri virtuali one-on-one durante tutto il convegno. Gli investitori istituzionali e i professionisti del settore possono scegliere di partecipare al convegno sia virtualmente che di persona presso il Lotte New York Palace Hotel.
Bone Biologics (Nasdaq: BBLG), un desarrollador de productos ortobiológicos para mercados de fusión espinal, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones de H.C. Wainwright. El evento está programado para el 9-11 de septiembre de 2024 en la ciudad de Nueva York. Jeffrey Frelick, CEO de la compañía, dará una presentación virtual, que estará accesible en línea a partir del 9 de septiembre a las 7:00 a.m. hora del Este.
La presentación seguirá disponible en el sitio web de la compañía por un tiempo. El equipo de gestión de Bone Biologics también estará disponible para reuniones virtuales uno a uno durante la conferencia. Los inversores institucionales y profesionales de la industria pueden optar por asistir a la conferencia de forma virtual o en persona en el Lotte New York Palace Hotel.
Bone Biologics (Nasdaq: BBLG)는 척추 융합 시장을 위한 오르토바이오로직 제품 개발업체로, H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕에서 열릴 예정입니다. 제프리 프레릭 CEO가 가상 발표를 진행하며, 이 발표는 9월 9일 동부 표준시 오전 7시부터 온라인으로 접근 가능합니다.
발표는 일정 기간 동안 회사 웹사이트에서 계속 제공될 예정입니다. Bone Biologics의 경영진 팀은 회의 기간 동안 가상 일대일 회의를 위해서도 대기할 것입니다. 기관 투자자 및 업계 전문가는 회의에 가상 또는 대면으로 참석할 수 있습니다, 장소는 Lotte New York Palace Hotel입니다.
Bone Biologics (Nasdaq: BBLG), un développeur de produits ortobiologiques pour le marché de la fusion vertébrale, a annoncé sa participation à la 26e Conférence Annuelle Mondiale d'Investissement d'H.C. Wainwright. L'événement est prévu du 9 au 11 septembre 2024, à New York. Jeffrey Frelick, le PDG de l'entreprise, présentera virtuellement, et cette présentation sera accessible en ligne à partir du 9 septembre à 7h00, heure de l'Est.
La présentation restera disponible sur le site web de l'entreprise pendant un certain temps. L'équipe de direction de Bone Biologics sera également disponible pour des réunions virtuelles individuelles tout au long de la conférence. Les investisseurs institutionnels et les professionnels de l'industrie peuvent choisir d'assister à la conférence soit virtuellement soit en personne à l'Lotte New York Palace Hotel.
Bone Biologics (Nasdaq: BBLG), ein Entwickler von orthobiologischen Produkten für den Markt der Wirbelsäulenfusion, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright angekündigt. Die Veranstaltung findet vom 9. bis 11. September 2024 in New York City statt. Jeffrey Frelick, der CEO des Unternehmens, wird eine virtuelle Präsentation halten, die ab dem 9. September um 7:00 Uhr Eastern Time online zugänglich sein wird.
Die Präsentation wird für eine Zeit lang auf der Unternehmenswebsite verfügbar bleiben. Das Management-Team von Bone Biologics wird während der Konferenz auch für virtuelle Einzelgespräche zur Verfügung stehen. Institutionelle Investoren und Fachleute aus der Branche können wählen, ob sie an der Konferenz virtuell oder persönlich im Lotte New York Palace Hotel teilnehmen möchten.
- None.
- None.
Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel.
About Bone Biologics
Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking work with select strategic partners that builds on the preclinical research of the Nell-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904108361/en/
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
Kgolodetz@lhai.com
Source: Bone Biologics Corporation
FAQ
When is Bone Biologics (BBLG) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Bone Biologics (BBLG) at the investment conference?
Where can I access Bone Biologics' (BBLG) presentation from the H.C. Wainwright conference?
Is it possible to meet with Bone Biologics (BBLG) management during the conference?
What are the attendance options for the H.C. Wainwright conference featuring Bone Biologics (BBLG)?
